S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
NASDAQ:CDNA

CareDx - CDNA Stock Forecast, Price & News

$13.22
+0.04 (+0.30%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.91
$13.43
50-Day Range
$12.06
$20.05
52-Week Range
$11.92
$47.82
Volume
807,436 shs
Average Volume
1.12 million shs
Market Capitalization
$707.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.20

CareDx MarketRank™ Forecast

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
249.5% Upside
$46.20 Price Target
Short Interest
Healthy
8.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.22mentions of CareDx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.44) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

537th out of 1,034 stocks

Medical Laboratories Industry

14th out of 25 stocks

CDNA stock logo

About CareDx (NASDAQ:CDNA) Stock

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Stock News Headlines

Do You Think CareDx (CDNA) Has Huge Growth Potential?
CareDx to Report Third Quarter 2022 Financial Results
CareDx, Inc. (NASDAQ: CDNA)
See More Headlines
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Company Calendar

Last Earnings
10/28/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDNA
Employees
633
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.20
High Stock Price Forecast
$87.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+249.5%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-30,660,000.00
Pretax Margin
-23.58%

Debt

Sales & Book Value

Annual Sales
$296.40 million
Book Value
$8.16 per share

Miscellaneous

Free Float
51,074,000
Market Cap
$707.80 million
Optionable
Optionable
Beta
0.89

Key Executives

  • Dr. Reginald SeetoDr. Reginald Seeto (Age 50)
    Pres, CEO & Director
    Comp: $1.51M
  • Dr. Peter Maag Ph.D. (Age 55)
    Exec. Director
    Comp: $791.45k
  • Ms. Sasha King M.B.A.Ms. Sasha King M.B.A. (Age 36)
    Exec. Officer
    Comp: $628.87k
  • Mr. Marcel Konrad (Age 46)
    Sr. VP of Fin. & Accounting
    Comp: $167.96k
  • Mr. Alexander L. Johnson (Age 48)
    Pres of Patient and Testing Services
    Comp: $716.54k
  • Mr. Abhishek Jain (Age 46)
    CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer
  • Ms. Marica Grskovic Ph.D.
    Chief Operating Officer
  • Mr. Abraham Ronai Esq. (Age 49)
    Gen. Counsel, Chief Admin. & Legal Officer and Sec.
  • Mr. Ian Cooney
    VP of Investor Relations
  • Dr. Mickey Y. Kim M.D.
    Sr. VP of Corp. Devel. & Head of Global Product













CDNA Stock - Frequently Asked Questions

Should I buy or sell CareDx stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CDNA shares.
View CDNA analyst ratings
or view top-rated stocks.

What is CareDx's stock price forecast for 2023?

4 equities research analysts have issued 1-year price objectives for CareDx's shares. Their CDNA share price forecasts range from $26.00 to $87.00. On average, they expect the company's share price to reach $46.20 in the next twelve months. This suggests a possible upside of 249.5% from the stock's current price.
View analysts price targets for CDNA
or view top-rated stocks among Wall Street analysts.

How have CDNA shares performed in 2022?

CareDx's stock was trading at $45.48 at the start of the year. Since then, CDNA stock has decreased by 70.9% and is now trading at $13.22.
View the best growth stocks for 2022 here
.

When is CareDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CDNA earnings forecast
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) released its quarterly earnings data on Thursday, October, 28th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.21. The business earned $75.60 million during the quarter, compared to analyst estimates of $74.11 million. CareDx had a negative net margin of 23.36% and a negative trailing twelve-month return on equity of 16.51%. The company's revenue was up 41.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.06) earnings per share.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $320.00 million-$325.00 million, compared to the consensus revenue estimate of $327.79 million.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.83%), Vanguard Group Inc. (9.46%), State Street Corp (7.93%), BlackRock Inc. (7.49%), Bellevue Group AG (4.86%) and Sumitomo Mitsui Trust Holdings Inc. (4.65%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends
.

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $13.22.

How much money does CareDx make?

CareDx (NASDAQ:CDNA) has a market capitalization of $707.80 million and generates $296.40 million in revenue each year. The company earns $-30,660,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does CareDx have?

The company employs 633 workers across the globe.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at caroline.corner@westwicke.com, or via fax at 415-287-2450.

This page (NASDAQ:CDNA) was last updated on 12/4/2022 by MarketBeat.com Staff